Tang Capital Management APGE Position
Exited11-Fund ConvergenceTang Capital Management exited their position in Apogee Therapeutics Inc. (APGE) in Q4 2025, after holding the stock for 8 quarters.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
APGE is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for APG777 in 228 days (Nov 30, 2026), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 23.2% of float with 10.9 days to cover, indicating significant bearish positioning against the stock.
About Apogee Therapeutics Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Full company profile →Short Interest
23.2%
10.9 days to cover
Tang Capital Management APGE Position History
Frequently Asked Questions
Does Tang Capital Management own APGE?
No. Tang Capital Management exited their position in Apogee Therapeutics Inc. (APGE) in Q4 2025. They previously held the stock for 8 quarters.
How many hedge funds own APGE?
11 specialist biotech hedge funds currently hold APGE, including RTW Investments, Perceptive Advisors, Driehaus Capital and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy APGE?
Tang Capital Management's position in APGE was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's APGE position increasing or decreasing?
Tang Capital Management completely exited their APGE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
APGECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →